Peter E. Boyd - 04 Dec 2025 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: Chief People Officer
Issuer ticker: AQST
Reported as of: 04 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Dec 2025, 13:06:06 UTC
Prior SEC filing: 17 Oct 2025
Next SEC filing: 11 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Lori Braender, as Attorney-In-Fact

Key filing fact

Peter E. Boyd filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 05 Dec 2025.

Key facts

This page summarizes Peter E. Boyd's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Dec 2025, 13:06.

Change

Previous filing in this sequence was filed on 17 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001739816 Primary reporting owner

Boyd Peter E.

Relationship: Chief People Officer
Address: C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN
Signature: /s/ Lori Braender, as Attorney-In-Fact
Signature date: 05 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Award

Transaction value: $0
Shares: +20,000
Change %: +7.5%
Price: $0.000000
Shares after: 288,323
Date: 04 Dec 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.